Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT Report 5)

British Journal of Ophthalmology

Volumn 97, Issue 9, 2013, Pages 1177-1180

  Sivaprasad, Sobha ^a   Crosby Nwaobi, Roxanne ^a   Heng, Ling Zhi ^a   Peto, Tunde ^a   Michaelides, Michel ^a   Hykin, Phil ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; HUMAN; INTERMETHOD COMPARISON; LASER SURGERY; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RETINA DETACHMENT; TREATMENT OUTCOME; VISUAL ACUITY;

CLINICAL TRIAL; DRUGS; MACULA; VISION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; LOGISTIC MODELS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84882266140     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-303168     Document Type: Article

References (16)

1. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119:1658-65.
2. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DAVINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011;118:1819-26.
3. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-57.
4. Diabetic Retinopathy Clinical Research NetworkElman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.
5. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-405.
6. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-62.
7. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 Phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
8. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078-86.
9. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130:972-9.
10. Kim NR, Kim YJ, Chin HS, et al. Optical coherence tomographic patterns in diabetic macular oedema: prediction of visual outcome after focal laser photocoagulation. Br J Ophthalmol 2009;93:901-5.
11. Kim M, Lee P, Kim Y, et al. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema. Ophthalmologica 2011;226:138-44.
12. Wu PC, Lai CH, Chen CL, et al. Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment. J Ocul Pharmacol Ther 2012;28:59-64.
13. Roh MI, Kim JH, Kwon OW. Features of optical coherence tomography are predictive of visual outcomes after intravitreal bevacizumab injection for diabetic macular edema. Ophthalmologica 2010;224:374-80.
14. Gaucher D, Sebah C, Erginay A, et al. Optical coherence tomography features during the evolution of serous retinal detachment in patients with diabetic macular edema. Am J Ophthalmol 2008;145:289-96.
15. Shin HJ, Lee SH, Chung H, et al. Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2012;250:61-70.
16. Murakami T, Nishijima K, Sakamoto A, et al. Association of pathomorphology, photoreceptor status, and retinal thickness with visual acuity in diabetic retinopathy. Am J Ophthalmol 2011;151:310-17.